Daptomycin is a cyclic lipopeptide antibiotic used to treat serious infections caused by Gram-positive bacteria [1]. It is particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) [2].
How does daptomycin work?
Daptomycin functions by disrupting the function of the bacterial cell membrane [3]. It inserts its lipid tail into the bacterial membrane, leading to rapid depolarization and loss of membrane potential. This inhibits protein, DNA, and RNA synthesis, ultimately resulting in bacterial cell death [4].
What infections can daptomycin treat?
Daptomycin is approved for treating complicated skin and skin structure infections (cSSSI) and Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis caused by susceptible Gram-positive bacteria [1]. It is often reserved for cases where other antibiotics are ineffective or not tolerated, due to its activity against resistant organisms like MRSA and vancomycin-resistant Enterococcus (VRE) [2].
When does daptomycin's patent protection expire?
Information regarding specific patent expiry dates for daptomycin can be found on resources like DrugPatentWatch.com [5].
Who are the main manufacturers of daptomycin?
The original developer of daptomycin was Cubist Pharmaceuticals, which was acquired by Merck & Co. [6]. Daptomycin is now available as both a branded product (Cubicin) and as a generic medication from various manufacturers [7].
What are the risks or side effects associated with daptomycin?
Common side effects of daptomycin include injection site reactions, headache, dizziness, nausea, vomiting, diarrhea, and constipation [1]. A more serious, though less common, side effect is muscle toxicity, characterized by elevated creatine phosphokinase (CPK) levels, which can lead to rhabdomyolysis [8]. Monitoring muscle strength and CPK levels is recommended during treatment [1]. Respiratory distress has also been reported, particularly in the context of co-administration with certain mechanical ventilation parameters [9].
Can biosimilars of daptomycin become available?
As daptomycin is a complex biologic molecule, its generic versions are considered biosimilars rather than simple generics. The availability and development of biosimilars can be influenced by patent status and regulatory pathways [5].
What is the difference between daptomycin and other antibiotics for MRSA?
Daptomycin offers a distinct mechanism of action compared to many other MRSA antibiotics, such as vancomycin or linezolid. Its membrane-disrupting activity can be advantageous in certain complex infections, especially when resistance to other agents is a concern [2][4]. However, daptomycin is not effective against Gram-negative bacteria and should not be used for Clostridioides difficile colitis [1].
How does daptomycin compare to vancomycin for MRSA infections?
Clinical trials have compared daptomycin to vancomycin for various MRSA infections. While both are effective, differences in efficacy and safety profiles exist. Daptomycin demonstrated non-inferiority to vancomycin for complicated skin and skin structure infections and was found to be superior in achieving microbiological cure in patients with S. aureus bacteremia and right-sided endocarditis in some studies, though it did not improve all-cause mortality in the bacteremia group [2][10]. The choice between daptomycin and vancomycin often depends on the specific infection, patient factors, and resistance patterns [2].